Object. Presently, the best available treatment for intramedullary spinal cord tumors (IMSCTs) in children is microsurgery with the objective of maximal tumor removal and minimal neurological morbidity. The latter has become manageable with the development and standard use of intraoperative neurophysiological monitoring. Traditionally, the perioperative neurological evaluation is based on surgical or spinal cord injury scores focusing on sensorimotor function. Little is known about the quality of life after such operations; therefore, this study was designed to investigate the impact of surgery for IMSCTs on the quality of life in children.
I
ntramedullary spinal cord tumors (IMSCTs) are rare, composing about 10% of all neoplasms of the CNS in children. 20 Presently, the best available treatment for IMSCTs is microsurgery with the objective of maximal tumor removal and minimal neurological morbidity. It has been shown that the oncological outcome for low-grade glial tumors depends on the extent of resection. However, once near-total resection is achieved, further removal of small remnants appears to provide no additional benefit. 7 Furthermore, this "last remnant" resection would logically carry the highest risk of surgery-induced neurological damage. The ability to avoid such neurological damage during surgery has improved with the development and standard use of intraoperative neurophysiological monitoring. 12, 14, 21 To evaluate neurological function pre-and postoperatively or to compare neurological function between groups, the McCormick Scale (often modified for pediatric needs) is widely used. 7, 16 The modified McCormick Scale (mMS) as well as other spinal cord injury scales focuses on more or less detailed neurological assessment ( Table 1) .
The more comprehensive question of patient quality of life (QOL)-particularly in the long term-is less well delineated by such functional scores and has not been studied in much detail. Any significant adverse effects of surgery upon a broader measure of QOL cannot be stud-ied in group comparisons, as there cannot be any studies comparing surgery with no surgery or comparing surgery with other isolated treatments such as radiation and/or chemotherapy. To overcome this limitation, we sought a tool to compare QOL in surgically treated patients with that in a normal group. It was assumed that considering the impact of the tumor itself and the additional effects of intramedullary resection, the QOL in the former patients would be worse than in the healthy population.
After reviewing available questionnaires, we determined that the Pediatric Quality of Life Questionnaire version 4 (PedsQL 4.0) seemed to be ideal for our purposes. It provides an overview of different dimensions of QOL, has adapted formulations for all age groups, utilizes parents or proxies for young or disabled children, and can also be used for adolescents and young adults. 26, 31 Most importantly, the instrument is validated for internal consistency over all age groups and is validly translated into different languages. Furthermore, normative data have been published to evaluate the impact of a specific disease compared with a healthy status. This latter aspect is especially useful given that the current study design is necessarily retrospective. 4, 9, 10, 15, [26] [27] [28] [29] [30] [31] 
Methods
The ethics committee of the Canton of Lucerne approved this retrospective fixed cohort study, which included 12 consecutive patients under the age of 18 years. They had all undergone microsurgical removal of an IMSCT performed by the senior author between 2005 and 2013 at the Cantonal Hospital of Lucerne. Intraoperative neurophysiological monitoring had been used in all cases. Patients with intradural extramedullary tumors and those with dysraphic conditions were excluded from analysis.
The mMS had been routinely used to evaluate neurological outcome (Table 1) in all patients at the time of diagnosis and at the follow-up. 16 The QOL study described in this paper was performed using the PedsQL 4.0, developed by Dr. James W. Varni (http://www.pedsql.org). 4, [26] [27] [28] [29] [30] [31] The German, Spanish, and Croatian translations of the PedsQL 4.0 were used. 9, 10, 15 Table 2 summarizes the 23 items calculated into the final QOL scores. Each item was scored as a number from 0 to 4 by the patient and/or the proxy, with 0 meaning no disability at all and 4 indicating maximal disability. These raw scores were transformed to a 0-100 scale (algorithm: 0 = 100, 1 = 75, 2 = 50, 3 = 25, 4 = 0) with 100 indicating the best possible function. Missing items were replaced by the arithmetic mean to calculate a subscore, provided that at least 50% of the items for each subscore were answered. Quality of life was assessed in 4 dimensions: 1) physical functioning, 2) emotional functioning, 3) social functioning, and 4) school functioning. The latter 3 dimensions were summarized as psychosocial functioning. The arithmetic mean over all 4 dimensions constituted the total score of the PedsQL 4.0. In older children and adolescents, the QOL data were reported by the patient him-or herself (Child Self Report [CSR]); in younger or severely disabled children, by the parents or proxies (Parent Proxy Report [PPR] ). For children between 5 and 7 years, an adapted CSR questionnaire provided visual analog pictograms of weeping and smiling faces to be pointed at. In these patients, an additional PPR was mandatory to complete the questionnaire, which explains why some patients had both CSR and PPR data. Questions varied a little according to age group; for example, other items replaced school func- tioning items for infants and toddlers. Nevertheless, the instrument has proved to be reasonably consistent for assessing QOL over all age groups. 30 Of the 12 patients eligible for this study, one boy had died of progressive disease; therefore, the PedsQL 4.0 was mailed to 11 patients and families. An informed consent form was mailed together with the questionnaire to be signed by the parents for children under 14 years of age, by the patient and parents for children over 14 but under 18 years, and by the patient if he or she was over 18 years at the time of follow-up. Nonresponders to the first mailing were sent a written reminder; nonresponders to this second mailing were contacted personally by telephone.
To evaluate the impact of an IMSCT on QOL, we used data from a large (more than 5000 individuals) healthy population sample. 26 Authors of the normative collective data give a certain value difference for each PedsQL 4.0 subscore that, when surpassed, delineates a "clinically important difference."
Using the GraphPad Prism software (version 6.02), we performed an unpaired t-test to compare patients and the healthy collective, assuming a level of significance of a = 5%. The same procedure was repeated for the subgroups of patients with low-grade and high-grade IMSCTs. On the basis of the abovementioned clinically important difference, a power calculation was performed to assess the number of patients ideally included in the study to reach a power of 0.8 using the 1-sample Z-test for a sample mean.
Results

Demographic and Clinical Data
Of the 12 patients eligible for analysis, 10 were male and 2 were female, with a mean age of 7.5 years (Table  3) . Histological diagnosis was high-grade tumor in 4 patients (1 glioblastoma, 2 anaplastic gangliogliomas, and 1 glioneuronal tumor) and low-grade tumor in 8 patients (5 pilocytic astrocytomas, 1 ganglioglioma, 1 hemangioblastoma, and 1 cavernoma). Patients in the low-grade group were slightly older at diagnosis with a mean age of 9.6 years as compared with a mean age of 5.3 years in the high-grade group. One patient in the high-grade group had died of progressive disease. Total resection was achieved in 5 patients and subtotal resection in 7. Four patients underwent 2 or more surgeries, 4 patients received adjuvant radiotherapy, and 6 patients received adjuvant chemotherapy. The mean mMS score for all patients at the time of diagnosis was 1.7; at the time of follow up, it was 1.5. No clinically important difference was calculated for either the low-grade or the high-grade group. 26 
Collection of QOL Data
Ten patients returned the questionnaire, resulting in a response rate of 91% (Table 3 ). The one nonresponder was contacted by telephone but gave no specific reason for not participating. All returned questionnaires were sufficiently completed to process the PedsQL 4.0 scores. Therefore, demographic and clinical data could be reported for 12 patients, whereas the QOL data refer to 10 patients (1 patient deceased and 1 nonresponder). The mean follow-up from the time of initial diagnosis to the date of a returned questionnaire was 4.2 years (2.4 years in the high-grade group, 5.9 years in the low-grade group). Table 4 provides a detailed description of the indi- (Varni et al., 2003) . It describes the standard error of measurement and was derived by multiplying the standard deviation of 1-alpha (Cronbach's alpha reliability coefficient) of the normative data. Transformed to the PedsQL 4.0 scores, it describes the minimal difference between a patient's score and the normative data that has a probability of less than 5% of being coincidental. vidual patients, including histological diagnosis, initial symptoms, spinal level of tumor occurrence, and treatment regimen as well as mMS scores and PedsQL 4.0 scores for each patient (Table 5) . For some of the PedsQL 4.0 subscores, a clinically important difference was noted in individual patients (Table 5 ), but these small differences did not affect overall QOL scores in the whole group (Figs. 1-3) . Figure 1 compares data from the normal collective with data in all patients with IMSCTs across the PedsQL 4.0 scores for CSR and PPR. There was no statistically significant difference between the study cohort and the normal sample population.
Results of QOL Assessment
When the patients were stratified into low-grade (Fig.  2) and high-grade (Fig. 3) groups, there was only one significant difference-in the physical functioning subscore of the CSR, not the PPR, indicating a slightly worse physical functioning situation in the low-grade group.
When performing the power calculation, assuming the clinically important difference as the minimal difference and the predefined level of significance of a = 5%, the following statements can be made: For the CSR total score, a sample size of 57 patients would be needed to reach a power of 0.8, and for the PPR total score, a sample size of 78 patients would be needed to reach a power of 0.8.
Discussion
Regarding the demographics of and histological diagnoses in the patients in this study, the findings were about as expected in the low-grade group. Pilocytic astrocytomas are the tumors most commonly found in the pediatric population. They can recur, and patients with such a recurrence usually undergo a second surgery and/ or receive adjuvant treatment. Based on original data presented by Constantini in 2000 and confirmed by McGirt in 2008, subtotal resection is oncologically sufficient for long-term survival, and thus adjuvant treatment would be the exception rather than the rule. 7, 18 It must be noted that every other patient in this series-even those with a low-grade tumor-received adjuvant treatment. This high proportion of patients with adjuvant treatment is amplified by the occurrence of 2 cases of a particularly rare tumor type, the anaplastic ganglioglioma in the highgrade group. 23 The occurrence of these rare tumors in our cohort may be due to a referral bias of complex cases to the senior author. The role of adjuvant radiotherapy is debated. It must be noted that in retrospective studies, there is some evidence of prolonged progression-free and overall survival, especially in high-grade IMSCTs and in ependymomas. 3, 11, 13, 24 A series of publications have already reported good outcomes (using the mMS) and determined the safety and efficacy of the best possible microsurgical tumor removal with the aid of intraoperative neurophysiological monitoring. 1, 2, [5] [6] [7] [8] 12, 14, 17, 18, 21, 25 No significant overall impact on reported QOL can be measured using the PedsQL 4.0 when comparing children with IMSCT and a healthy collective. There is only one minor exception to this conclusion: in the physical health item of the CSR score in the low-grade subgroup (Fig. 2) , the t-test revealed a significant impact of the disease at an error level of 5%. This significance disappeared when combining CSR and PPR in this group. However, this finding indicates a potential tendency for the physical health item to be the first to be affected by IMSCT surgery if a larger patient group could be studied. of significant neurological and orthopedic sequelae.
22
Even though these authors did not report a formal QOL assessment, the data indicated either the possibility of later deterioration or some other bias in the patient group as determined by disease, surgery, or adjuvant treatment. Particularly, late spinal deformities can occur after multilevel laminectomies. 19, 32 The retrospective nature, small patient group, referral bias, group inhomogeneity, and high number of patients needed to reach a power of 0.8 are certainly weaknesses of this study. To include 50-70 patients is impossible, as these cases are simply not treated within a reasonable time frame given the low incidence of the disease. That is precisely one important reason to use a standardized and validated instrument to assess a multidimensional issue such as QOL to compare even a small patient group with a healthy collective and still have a meaningful study design with known numerical power.
Such an assessment has not been reported. Since the value of surgery for diagnosis and its documented oncological benefit are established, no prospective study comparing surgery with adjuvant treatments is conceivable. Therefore, particular aspects of treatment, such as QOL in the present report, must be studied in other ways. Comparing the study cohort-with its common denominator of surgical treatment-with a normal sample appeared to be logical.
It is somewhat surprising that no differences were found in the QOL of patients compared with that in the normal collective. With a serious disease and a serious operation as in IMSCTs, it would have been intuitively obvious to expect a less than normal QOL. Furthermore, the study cohort was fixed by the surgery, which all patients had in common. And the fact that many patients underwent additional treatments, which may well have adversely affected QOL, did not push the results toward a worse status. It is possible though that in a larger study population, a small impact on QOL data would have reached statistical significance, as delineated in the power calculation.
Moreover, there may be a proxy bias. Parents sometimes take great efforts to obtain specialized surgical treatment, even abroad, and may tend to have a more positive view of their children's QOL status. It is also very probable that patients with a long interval from diagnosis to QOL assessment report a better clinical status (a "happy to have survived" bias).
Finally, the high response rate for a questionnairebased mail-in study is unusual. 26 It may be explained by the close interaction among patients, families, and caregivers for the management of a complex condition.
Conclusions
In children with surgically treated IMSCT, QOL measured with the PedsQL 4.0 is not different from that in a healthy collective after a mean follow-up of 4.2 years. This conclusion is drawn with an awareness of the small patient group, but still is an encouraging finding and can be emphasized when surgery is discussed with patients and parents confronted with this disorder.
